SecBot SecBot
8-K ·Filed Aug 12, 2026

ABUS

Arbutus Biopharma Corp
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001171843-26-005442
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The capital return plan (up to ~$230M, ~25% of market cap) and the Pfizer/BioNTech LNP lawsuits are the primary catalysts. Monitor for the specific form of the tender offer/buyback and any developments in the international patent litigation. The imdusiran Phase 2b alignment is a positive pipeline de-risking event.

DirectionBullish
Confidencehigh
Horizonweeks

imdusiran

● Neutral Named in this 8-K
Impact
Phase
Phase 2 (completed); Phase 2b planned
Time to market
Unknown — likely several years out. Phase 2b design is FDA-aligned but the trial had not been initiated as of the Aug 2026 update; a registrational Phase 3 and filing would still follow, so 2028+ at the earliest if all goes well.
Next catalyst
None dated

What to watchNear-term share-price drivers are the $230M Dutch-auction tender offer (expires Sept 29, 2026, at $5.00–$5.75) and the LNP patent lawsuits vs. Pfizer/BioNTech; watch for Phase 2b initiation announcements and conference data updates for imdusiran specifically.

Price Chart

Loading chart...

Executive Summary

Arbutus Biopharma reported Q2 2026 results with a net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025, driven by the absence of the prior year's $9.6M Qilu partnership revenue recognition. The company received $178.4M from the Moderna settlement in July and announced a plan to return up to ~$230M to shareholders via share repurchases, while also filing three international LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and the Pfizer/BioNTech litigation catalyst, not the operational quarter.

Key Financial Metrics

EPS
−$0.03
est −$0.03 · 0.0%
Revenue
$1.0M
est $961.0K · +5.6% · -90.6% YoY
Rating
miss

Key Facts

  • Q2 2026 net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025
  • Total revenue fell to $1.0M from $10.7M YoY due to prior-year Qilu partnership revenue recognition
  • Received $178.4M from Moderna settlement in July 2026
  • Plans to return up to ~$230M to shareholders via share repurchases starting Q3 2026
  • Filed three international LNP patent enforcement lawsuits against Pfizer/BioNTech across 21 countries
  • FDA alignment achieved on Phase 2b trial design for imdusiran in chronic hepatitis B
  • Cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Financial Impact

Up to $230M capital return to shareholders; $178.4M Moderna settlement payment received; $1.3B contingent payment possible from Moderna; Pfizer/BioNTech LNP lawsuits with unquantified potential

cashshare countlitigation exposure

Risk Factors

  • Capital return plan is subject to board approval and may not occur
  • Pfizer/BioNTech lawsuits are early-stage and face significant legal hurdles
  • Moderna contingent payment of $1.3B depends on appellate ruling on 28 U.S.C. 1498
  • Operating cash burn continues ($14.1M in H1 2026)
  • Imdusiran remains in clinical development with no guarantee of regulatory approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005442
Document: f8k_081226.htm0001171843-26-005442
Document: 0001171843-26-005442-index-headers.html0001171843-26-005442
Document: 0001171843-26-005442-index.html0001171843-26-005442
Document: 0001171843-26-005442.txt0001171843-26-005442
8-K Data (Synthetic)0001171843-26-005442

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026